BRIEF—KSQ Therapeutics secures $80 million in series C round

KSQ Therapeutics has secured $80 million in a series C financing aimed at advancing oncology drug candidates generated from the company’s proprietary CRISPRomics drug discovery engine into clinical studies.

The firm says its first program, a modified adoptive T-cell immunotherapy, will enter the clinic within the next 18 months.

KSQ says it continues to expand CRISPRomics for use in other therapeutic areas, including immunology and rare diseases.